ArticleCommunications biology2019
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 74 citations in OpenAlex.
- PEGylated IL2 and tumor-targeted radiotherapy augment CD8Theranostics · 2026Trial
- Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.Journal for immunotherapy of cancer · 2026Article
- Enhanced Antitumor Efficacy ofInternational journal of radiation oncology, biology, physics · 2026Article
- Enhanced Response to Radiopharmaceutical Therapy in Preclinical Tumor Models with XRD-0394, a Dual Inhibitor of ATM Kinase and DNA-PKcs.Radiation research · 2026Article
- Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS-STING pathway: mechanisms, challenges, and combination therapy strategies.Molecular cancer · 2026Review
- Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice.Nature communications · 2026Article
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3.Theranostics · 2026Article
- The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.Military Medical Research · 2026Review
- A Trifunctional, Rare-Earth Theranostic Chelator Platform to Enable Diagnostic Nuclear Imaging, Surgical Resection, and Radiotherapy.Journal of the American Chemical Society · 2025Article
- LiposomalCancer science · 2025Article
- The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy.Cancer immunology research · 2025Article
- Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.International journal of molecular sciences · 2025Review
- Low-dose radiation by radiopharmaceutical therapy enhances GD2Science advances · 2025Article
- Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors.Applied radiation oncology · 2025Article
- Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer.Frontiers in immunology · 2025Article
- Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors.Radiation (Multidisciplinary Digital Publishing Institute) · 2025Article
- Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy usingJournal for immunotherapy of cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Reinier HernandezDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Kirsti L WalkerDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Joseph J GrudzinskiDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Eduardo Aluicio-SarduyDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ravi PatelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Christopher D ZahmUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Anatoly N PinchukDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Christopher F MasseyDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ariana N BittonDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ryan J BrownDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Paul M SondelDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jonathan W EngleDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Christian M CapitiniDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID http://orcid.org/0000-0002-2276-6731
Jamey P WeichertDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. jweichert@uwhealth.org.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6MRESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MInhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapyK08CA174750 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAPITINI, CHRISTIAN · 2014 to 2017
$715kNCI NIH HHS K08 CA174750NCI NIH HHS P30 CA014520NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233102NHLBI NIH HHS T32 HL007899NIH HHS DP5 OD024576
Abstract
Finding improved therapeutic strategies against T-cell Non-Hodgkin's Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targeting alkylphosphocholine (NM600) radiolabeled with
Indexed as
AnimalsCell Line, TumorFemaleHumansImmunologic MemoryLymphoma, T-CellMice, Inbred C57BLMice, KnockoutMice, SCIDPositron-Emission TomographyTissue DistributionTumor BurdenTumor Protein, Translationally-Controlled 1Xenograft Model Antitumor AssaysYttrium RadioisotopesTpt1 protein, mouseTumor Protein, Translationally-Controlled 1Yttrium-86Yttrium Radioisotopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.